COMBINATION THERAPY WITH AN ANTITUMOR ALKALOID

589269 Disclosed is the use of PM00104, or a pharmaceutically acceptable salt thereof, in combination with another anticancer drug selected from tyrosine kinase inhibitors, mTOR inhibitors, antitumor platinum coordination complexes, antimetabolites, anthracyclines, topoisomerase I and/or II inhibitors, and antitumor monoclonal antibodies, for the manufacture of a medicament for the treatment of a cancer selected from lung cancer, pleural mesothelioma, bladder carcinoma, pancreas carcinoma, gastric carcinoma, ovarian cancer, and breast cancer, wherein the medicament comprises synergistic properties.